FluxMPS™ Basal Medium Eagle (BME): 1X Liquid

FluxMPS™ Basal Medium Eagle (BME), 1X Liquid

FluxMPS™ Basal Medium Eagle (BME), 1X Liquid is a Microfluidics Suitable, ultra-filtered cell culture medium manufactured through a validated Quadruple-stage filtration system (0.1 µm ×2 + 0.04 µm ×2) reaching a 0.04 µm final cut-off — five times finer than the 0.22 µm membranes used for conventional sterile filtration. Engineered for microfluidic channels, organ-on-a-chip (OoC), and microphysiological system (MPS) platforms where sub-micron particulates cause sensor drift, microchannel occlusion, and compromised cell viability.

• Quadruple-stage nanofiltration train: 0.1 µm pre-filter ×2 + 0.04 µm final filter ×2, reaching a 0.04 µm final cut-off
• Endotoxin release specification: < 0.05 EU/mL (LAL, USP <85> Bacterial Endotoxins Test), tested per manufacturing batch
• Complete Eagle’s Basal Medium formulation with D-Glucose (1,000 mg/L), L-Glutamine (292 mg/L) and Phenol Red (11 mg/L) indicator; sodium pyruvate is not included
• Sodium bicarbonate-buffered (2,200 mg/L NaHCO₃) for use in a 5% CO₂ atmosphere
• Prepared with Ultrapure Type 1 water (18.2 MΩ·cm), minimizing trace-metal and organic-carbon background
• Manufactured under an ISO 13485:2016 quality management system; aseptic fill and finish in Totowa, NJ
• Custom formulations available — pH, glucose, HEPES, salts, and nutrient composition on request

Engineered where standard media fails

Conventional 0.22 µm-filtered Basal Medium Eagle passes mycoplasma-scale particles (0.2–0.3 µm), sub-visible aggregates, and endotoxin fragments that clog microfluidic channels and corrupt downstream biosensor or TEER signals. FluxMPS™ BME addresses these failure modes with a four-stage nanofiltration train and an ISO 13485:2016 quality system.^[1,2]

Quadruple-stage filtration system

FluxMPS™ BME is manufactured through a validated four-stage nanofiltration train terminating at a 0.04 µm final cut-off — five times finer than the 0.22 µm membranes used in conventional single-pass filtration. The train runs two dedicated 0.1 µm prefilter + 0.04 µm final-filter pairs in series, each pair providing full redundancy for the one behind it.

1. 1

   0.1 µm Prefiltration I

   First-pass removal of large aggregates, cell debris, and macro-particulates. Extends downstream membrane life and reduces bioburden load ahead of the first 0.04 µm final filter.

2. 2

   0.04 µm Final Filtration I

   First 0.04 µm pass, retaining sub-micron particulates and microaggregates that pass through a 0.22 µm membrane.

3. 3

   0.1 µm Prefiltration II

   Second dedicated 0.1 µm prefilter, protecting the second 0.04 µm cartridge and providing full process redundancy ahead of final filtration.

4. 4

   0.04 µm Final Filtration II — Polish

   Ultimate 0.04 µm polishing pass immediately prior to aseptic fill and finish, reducing sub-visible particulate load before container closure.

Optimized for next-generation cell platforms

FluxMPS™ BME’s clean formulation, defined ionic balance, and microchannel-safe particulate profile make it a suitable basal medium for demanding research platforms — from organ-on-a-chip perfusion systems to metabolomics and live-cell optical sensing.^[1,4,6]

Automated Bioreactors & Robotics

For automated perfusion bioreactors, robotic liquid-handling platforms, and high-throughput microfluidic screening systems, an optional MPS Grade 0.01 µm (10 nm) ultra nano-filtered variant of FluxMPS™ BME is available, adding two further filtration stages beyond this Microfluidics Suitable product’s 0.04 µm cut-off. This grade provides near-absolute exclusion of nanoparticulates, protecting precision valves, flow sensors, and sub-micron microchannels from fouling during extended automated runs.

• Total Particulate Exclusion: 0.01 µm filtration removes nanoparticulates that transit standard 0.04 µm membranes, reducing cumulative fouling in long-duration perfusion experiments
• Valve & Sensor Protection: Ultra-clean media extends the operational lifetime of microfluidic valves, pressure transducers, and optical flow sensors in automated bioreactor systems
• Extended Perfusion Stability: Reduced particulate load supports stable TEER, impedance, and biosensor readings across multi-week perfusion protocols

Inquiry Required: The 0.01 µm (10 nm) MPS Grade is produced on a project basis. To request this specification, contact support@diagnocine.com.

Analytical & quality release data

Each lot of FluxMPS™ BME is released against a Certificate of Analysis covering physical, chemical, sterility, and particulate parameters, measured by validated USP and ISO methods with full traceability to raw material lots.

Full composition (mg/L)

Complete formulation of FluxMPS™ Basal Medium Eagle (BME), 1X Liquid — 30 components across 4 categories. All values in mg/L; CAS numbers provided for reference. Every ingredient is released per-lot against this specification. Custom adjustments to any component — including L-Glutamine, HEPES, glucose, or salt concentrations — are available on request.

Built under a rigorous quality system

FluxMPS™ BME is manufactured in Totowa, NJ, USA under an ISO 13485:2016 Quality Management System, with 21 CFR Part 820 (QMSR) alignment. Every production step — from raw material receipt through final aseptic fill — is documented and traceable.

How FluxMPS™ BME compares

FluxMPS™ BME is benchmarked below against conventional 0.22 µm single-pass filtered BME formulations. Where a competitor does not publish a comparable figure, the cell reads “Not specified” rather than an estimate.

Comparison figures from published supplier specifications, accessed 2 September 2026. Suppliers that publish no numeric endotoxin specification are shown as “Not specified”.

Frequently asked questions

Common questions about FluxMPS™ Basal Medium Eagle (BME), 1X Liquid — filtration, formulation, supplementation, and quality assurance.

Supporting literature

Peer-reviewed publications supporting the use of ultra-filtered basal media in organ-on-a-chip, microfluidic perfusion, metabolomics, vascular biology, and live-cell imaging applications.

1. Huh D, Hamilton GA, Ingber DE. From 3D cell culture to organs-on-chips. Trends Cell Biol. 2011;21(12):745–754.doi:10.1016/j.tcb.2011.09.005
2. Bhatia SN, Ingber DE. Microfluidic organs-on-chips. Nat Biotechnol. 2014;32(8):760–772.doi:10.1038/nbt.2989
3. Vander Heiden MG, Cantley LC, Thompson CB. Understanding the Warburg effect: the metabolic requirements of cell proliferation. Science. 2009;324(5930):1029–1033.doi:10.1126/science.1160809
4. Pampaloni F, Reynaud EG, Stelzer EH. The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol. 2007;8(10):839–845.doi:10.1038/nrm2236
5. van der Meer AD, van den Berg A. Organs-on-chips: breaking the in vitro impasse. Integr Biol. 2012;4(5):461–470.doi:10.1039/c2ib00176d
6. Beebe DJ, Ingber DE, den Toonder J. Organs on Chips 2013. Lab Chip. 2013;13(18):3447–3448.doi:10.1039/c3lc90080k
7. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126(4):663–676.doi:10.1016/j.cell.2006.07.024
8. Metallo CM, Vander Heiden MG. Understanding metabolic regulation and its influence on cell physiology. Mol Cell. 2013;49(3):388–398.doi:10.1016/j.molcel.2013.01.018
9. Ronaldson-Bouchard K, Vunjak-Novakovic G. Organs-on-a-chip: a fast track for engineered human tissues in drug development. Cell Stem Cell. 2018;22(3):310–324.doi:10.1016/j.stem.2018.02.011
10. Zhang YS, Aleman J, Shin SR, et al. Multisensor-integrated organs-on-chips platform for automated and continual in situ monitoring of organoid behaviors. Proc Natl Acad Sci USA. 2017;114(12):E2293–E2302.doi:10.1073/pnas.1612906114